Literature DB >> 2306412

99mTc-neoglycoalbumin (NGA)-binding to human hepatic binding protein (HBP) in vitro.

I Virgolini1, P Angelberger, C Müller, J O'Grady, H Sinzinger.   

Abstract

1 Neoglycoalbumin (NGA) was synthesised by covalent coupling of 2-imino-2-methoxyethyl-1-thio-beta-D-galactopyranoside (IME-thiogalactose) to the primary amino groups of human serum albumin (HSA). NGA was purified by ultrafiltration and size exclusion h.p.l.c. (SEC). 99mTc-labelling was performed with and without SEC purification. 2 Estimation of 99mTc-NGA-binding to human hepatic binding protein (HBP) revealed a complex behaviour indicating saturable high- and low-affinity sites. The high-affinity binding capacity was 1.1 +/- 0.4 pmol mg-1 human liver plasma membrane protein, the low-affinity binding capacity was 6.2 +/- 1.8 pmol mg-1 liver plasma membrane protein. The apparent equilibrium dissociation constants were 2.4 +/- 1.2 and 18.4 +/- 4.8 nM, respectively. 3 Specific binding of 99mTc-NGA to human HBP in the presence of 100 microM unlabelled NGA, Ca++ and Mg++ at pH 7.5 and 37 degrees C reached 85 +/- 5% at equilibrium. The amount of ligand specifically bound increased with the amount of human liver membrane protein added. The concentration of unlabelled agonist necessary to displace 50% of ligand bound amounted to 100 nM.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306412      PMCID: PMC1380085          DOI: 10.1111/j.1365-2125.1990.tb03621.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Blocking of hog intrinsic factor by human gastric juice and certain mucopolysaccharides, including blood group substance.

Authors:  Z CASTRO; V HERBERT; L R WASSERMAN
Journal:  J Clin Invest       Date:  1961-01       Impact factor: 14.808

2.  A graphic method for the determination and presentation of binding parameters in a complex system.

Authors:  H E Rosenthal
Journal:  Anal Biochem       Date:  1967-09       Impact factor: 3.365

3.  Evaluation of prostaglandin-receptors in human and rat liver: interspecies differences at the prostaglandin receptor-level.

Authors:  I Virgolini; C Müller; M Hermann; W Schütz; H Sinzinger
Journal:  Prostaglandins       Date:  1988-12

4.  The binding of desialylated glycoproteins by plasma membranes of rat liver. Development of a quantitative inhibition assay.

Authors:  L Van Lenten; G Ashwell
Journal:  J Biol Chem       Date:  1972-07-25       Impact factor: 5.157

5.  Isolation of an organ specific protein antigen from cell-surface membrane of rat liver.

Authors:  D M Neville
Journal:  Biochim Biophys Acta       Date:  1968-04-09

6.  Technetium-99m galactosyl-neoglycoalbumin: preparation and preclinical studies.

Authors:  D R Vera; R C Stadalnik; K A Krohn
Journal:  J Nucl Med       Date:  1985-10       Impact factor: 10.057

7.  Physical and chemical studies on ceruloplasmin. IV. Preparation of radioactive, sialic acid-free ceruloplasmin labeled with tritium on terminal D-galactose residues.

Authors:  A G Morell; C J Van den Hamer; I H Scheinberg; G Ashwell
Journal:  J Biol Chem       Date:  1966-08-25       Impact factor: 5.157

8.  Tc-99m galactosyl-neoglycoalbumin: in vitro characterization of receptor-mediated binding.

Authors:  D R Vera; K A Krohn; R C Stadalnik; P O Scheibe
Journal:  J Nucl Med       Date:  1984-07       Impact factor: 10.057

9.  Technetium-99m NGA functional hepatic imaging: preliminary clinical experience.

Authors:  R C Stadalnik; D R Vera; E S Woodle; W L Trudeau; B A Porter; R E Ward; K A Krohn; L F O'Grady
Journal:  J Nucl Med       Date:  1985-11       Impact factor: 10.057

10.  Decrease of prostaglandin I2 binding sites in thyroid cancer.

Authors:  I Virgolini; M Hermann; H Sinzinger
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

View more
  4 in total

1.  Development of ⁶⁸Ga-labelled DTPA galactosyl human serum albumin for liver function imaging.

Authors:  Roland Haubner; David R Vera; Salman Farshchi-Heydari; Anna Helbok; Christine Rangger; Daniel Putzer; Irene J Virgolini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-12       Impact factor: 9.236

2.  Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand.

Authors:  I Virgolini; C Müller; W Klepetko; P Angelberger; H Bergmann; J O'Grady; H Sinzinger
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

3.  Scintigraphic evaluation of functional hepatic mass in patients with advanced breast cancer.

Authors:  I Virgolini; G Kornek; J Höbart; S R Li; M Raolerer; H Bergmann; W Scheithauer; T Pantev; P Angelberger; H Sinzinger
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

4.  Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression.

Authors:  Jennifer L S Willoughby; Amy Chan; Alfica Sehgal; James S Butler; Jayaprakash K Nair; Tim Racie; Svetlana Shulga-Morskaya; Tuyen Nguyen; Kun Qian; Kristina Yucius; Klaus Charisse; Theo J C van Berkel; Muthiah Manoharan; Kallanthottathil G Rajeev; Martin A Maier; Vasant Jadhav; Tracy S Zimmermann
Journal:  Mol Ther       Date:  2017-09-07       Impact factor: 11.454

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.